MYC Oncogene in Cancer: Cancer Cell Intrinsic and Immune Inhibitory Functions
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 147
Special Issue Editors
Interests: molecular oncology; immunology; microbiology; tumor microenvironment
Special Issue Information
Dear Colleagues,
The MYC oncogene is a critical driver of tumorigenesis, regulating diverse processes essential for cancer cell survival, proliferation, and metabolic reprogramming. Its intrinsic oncogenic functions enable uncontrolled cellular growth, promoting genetic instability and resistance to apoptosis. Beyond these cell-autonomous effects, MYC plays a pivotal role in shaping the tumor microenvironment by exerting immune-inhibitory effects. MYC-driven cancers exploit mechanisms such as immunosuppressive cytokine secretion, recruitment of regulatory immune cells, and modulation of antigen presentation to evade immune surveillance. This duality of MYC function highlights its significance as both a driver of intrinsic oncogenic pathways and a regulator of the immune landscape in cancer. Therapeutic strategies targeting MYC, including indirect inhibition and immune modulators, represent promising approaches to disrupt its multifaceted role in tumor progression. Understanding the interplay between MYC’s oncogenic and immune-regulatory functions is essential for developing targeted therapies to mitigate its oncogenic potential.
Dr. Wadie Mahauad Fernandez
Dr. Konstantinos V. Floros
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MYC oncogene
- molecular oncology
- immuno-oncology
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
